Cambridge, UK and Cambridge, Massachusetts – 19 April 2006 – Acambis plc (Acambis) (LSE: ACM, NASDAQ: ACAM) announces that it has completed enrolment into two pivotal Phase 3 trials of its investigational vaccine against Japanese encephalitis (JE), ChimeriVax-JE, ahead of schedule. With this milestone met, Acambis remains on track for preparing the ChimeriVax-JE licence applications for submission in India and Australia in 2007.
